2009 2.5 Gy per f 138.9) Belliere A 74 Gy 50 Stage IIIA/B 2009 Campeau 60 Gy in 30 f 73 Stage I 18 2 year 57% w MP w chemo months chemo 2009 60 Gy in 30 f (1-81) 33% w/o w/o chemo chemo 50-55 Gy in 20 f Sura S IMRT 55 Stage I-IIIB 26 2 year Stage I/II 2008 months I/II 55% 50% Stage III 58% Stage III 58% Low JSh 55 Gy 23 Stage I 18.9 2 year 54.7% 2007 months 3 year 24.3% (6.2- 117.4) Sura S 80 Gy 55 I/II 5 year I/II ≥ 2007 27 Stage IIIA/B I/II 36% 67% Stage IIIA/B Stage 31% IIIA/B 39% Faria SL 52.5 Gy in 15 32 Stage T1-2 2 year 56% 2006 f hyper Fang LC 66 GY 85 Stage I 19 2 year 77% 68% 2006 Months 5 year 70% 36% (3-77) Chen M 63 to 102.9 106 Stage I-III 104 1 year 86% 2006 Gy in 2.1 Gy recurrent months 2 years 61% f 3 years 43% 4 years 21% Kong FM 106 I-III 5 year 63-69 Gy 4% 63 to 103 Gy 2005 in 2.1 Gy f recurrent 74-84 Gy 22% 92-103 Gy 28% Rosenzweig 70.2 Gy 32 early stage 2 year 54% KE 5 year 33% 2001 Systematic Reviews of CyberKnife None provided. Reported two year control ranged from 87.5% (n=8) to 100% (n=20) in the CyberKnife studies compared to 67% (n=55) to 77% (n=85) in the studies on 3DCRT. Two year survival ranged from 62% (n=39) to 90% (n=20) in the CyberKnife studies compared to 54.7% (n=23) to 61% (n=106) in the studies reporting on 3DCRT. Longer term data were available for patients in the 3DCRT studies (5 years) with one CyberKnife study reporting overall survival at 4.5 years.
2009 2.5 Gy per f 138.9) Belliere A 2009 74 Gy 50 Stage IIIA/B Campeau MP 2009 60 Gy in 30 f w chemo 60 Gy in 30 f w/o chemo 50-55 Gy in 20 f 73 Stage I 18 months (1-81) 2 year 57% w chemo 33% w/o chemo Sura S 2008 IMRT 55 Stage I-IIIB 26 months 2 year Stage I/II 50% Stage III 58% I/II 55% Stage III 58% Low JSh 2007 55 Gy 23 Stage I 18.9 months (6.2- 117.4) 2 year 3 year 54.7% 24.3% Sura S 2007 ≥ 80 Gy 55 I/II 27 Stage IIIA/B 5 year I/II 67% Stage IIIA/B 39% I/II 36% Stage IIIA/B 31% Faria SL 2006 52.5 Gy in 15 f hyper 32 Stage T1-2 2 year 56% Fang LC 2006 66 GY 85 Stage I 19 Months (3-77) 2 year 5 year 77% 70% 68% 36% Chen M 2006 63 to 102.9 Gy in 2.1 Gy f 106 Stage I-III recurrent 104 months 1 year 2 years 3 years 4 years 86% 61% 43% 21% Kong FM 2005 63 to 103 Gy in 2.1 Gy f 106 I-III recurrent 5 year 63-69 Gy 4% 74-84 Gy 22% 92-103 Gy 28% Rosenzweig KE 2001 70.2 Gy 32 early stage 2 year 5 year 54% 33% Systematic Reviews of CyberKnife None provided. Reported two year control ranged from 87.5% (n=8) to 100% (n=20) in the CyberKnife studies compared to 67% (n=55) to 77% (n=85) in the studies on 3DCRT. Two year survival ranged from 62% (n=39) to 90% (n=20) in the CyberKnife studies compared to 54.7% (n=23) to 61% (n=106) in the studies reporting on 3DCRT. Longer term data were available for patients in the 3DCRT studies (5 years) with one CyberKnife study reporting overall survival at 4.5 years.
1158-PSD-Roboticimage-guidedsterotacticprecisebeamradiosurgeryandradiotherapy-Accessible%20(D13-1620678)%20(D13-1647459).docx